Pharmacokinetics and Bioequivalence Study of a New Branded Generic Moxifloxacin Tablet Among Healthy Volunteers.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical pharmacology in drug development"
DOI: 10.1002/cpdd.964
Abstract: A newly developed branded generic of a moxifloxacin (MOX) 400-mg tablet formulation was manufactured prior to this study. A bioequivalence (BE) study was done to assess the pharmacokinetics of the formulation using a randomized, open-label,… read more here.
Keywords: branded generic; formulation; generic moxifloxacin; bioequivalence study ... See more keywords
Effects of Medicare Part D coverage gap closure on utilization of branded and generic drugs
Sign Up to like & getrecommendations! Published in 2022 at "Health Economics"
DOI: 10.1002/hec.4637
Abstract: Abstract The Affordable Care Act included a provision to gradually eliminate the Medicare prescription drug coverage gap between 2011 and 2020, which substantially lower medication costs in the gap. Using 2007–2016 Medicare claims data, we… read more here.
Keywords: generic drugs; branded generic; coverage gap; gap ... See more keywords
Targeted active surveillance of branded generic deferasirox in pediatric thalassemia patients in a tertiary care hospital of India: A pharmacovigilance study
Sign Up to like & getrecommendations! Published in 2025 at "Indian Journal of Pharmacology"
DOI: 10.4103/ijp.ijp_88_23
Abstract: Abstract: INTRODUCTION: Deferasirox is a newer oral iron chelator which needs to be given for at least 1 year to see a significant decrease in serum ferritin level in thalassemia patients with chronic iron overload.… read more here.
Keywords: hospital; branded generic; thalassemia; generic deferasirox ... See more keywords